Details for Patent: 8,633,219
✉ Email this page to a colleague
Which drugs does patent 8,633,219 protect, and when does it expire?
Patent 8,633,219 protects GENVOYA and STRIBILD and is included in two NDAs.
Protection for GENVOYA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seven patent family members in three countries.
Summary for Patent: 8,633,219
| Title: | Combination therapy |
| Abstract: | The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-meth- oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ("Compound A") or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans. |
| Inventor(s): | Matsuzaki; Yuji (Osaka, JP), Watanabe; Wataru (Osaka, JP), Ikeda; Satoru (Osaka, JP), Kano; Mitsuki (Osaka, JP) |
| Assignee: | Japan Tobacco Inc. (Tokyo, JP) |
| Application Number: | 11/133,463 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,633,219 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 8,633,219
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Gilead Sciences Inc | STRIBILD | cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 203100-001 | Aug 27, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,633,219
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1758581 | ⤷ Try a Trial | |||
| European Patent Office | 2229945 | ⤷ Try a Trial | |||
| European Patent Office | 2332538 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
